Anti-MIIP antibody (ab167197)
Key features and details
- Mouse polyclonal to MIIP
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-MIIP antibody
See all MIIP primary antibodies -
Description
Mouse polyclonal to MIIP -
Host species
Mouse -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant full length protein, corresponding to amino acids 1-388 of Human MIIP (AAH08068.1).
-
Positive control
- Lysate of 293T cells transfected with MIIP.
-
General notes
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
Storage buffer
pH: 7.4
Constituent: 99% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab167197 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | Use a concentration of 1 µg/ml. Predicted molecular weight: 43 kDa. |
Target
-
Relevance
MIIP has 3 SEG (segments of low compositional complexity) domains, an RGD motif, and several potential phosphorylation sites. The C-terminal region of IGFBP2 interacts with a central 44-amino acid sequence of MIIP. MIIP inhibits glioma cells invasion and down-regulates adhesion- and motility-associated genes such as NFKB2 and ICAM1. It exhibits opposing effects to IGFBP2 on cell invasion. There are 2 named isoforms due to alternative splicing. Isoform 1 is expressed in brain but underexpressed in glioma tissues, at protein level. Isoform 2 is not detected in normal organs, but is expressed in gliomas with increasing levels with glioma progression. On the contrary, at protein level, isoform 2 is not detected in gliomas, suggesting that this isoform is unstable in glioma cells. Isoform 2 is degraded by the ubiquitin-proteasome pathway. -
Database links
- Entrez Gene: 60672 Human
- Omim: 608772 Human
- SwissProt: Q5JXC2 Human
- Unigene: 8595 Human
-
Alternative names
- FLJ12438 antibody
- FLJ38609 antibody
- IGFBP 2 binding protein antibody
see all
Images
-
All lanes : Anti-MIIP antibody (ab167197) at 1 µg/ml
Lane 1 : Lysate of 293T cells transfected with MIIP
Lane 2 : Lysate of 293T cells (non-transfected)
Lysates/proteins at 15 µl per lane.
Secondary
All lanes : Goat anti-mouse HRP conjugated antibody at 1/2500 dilution
Predicted band size: 43 kDa
Datasheets and documents
References (0)
ab167197 has not yet been referenced specifically in any publications.